tradingkey.logo

Castle Biosciences Inc

CSTL
查看详细走势图
40.090USD
-0.110-0.27%
收盘 12/24, 13:00美东报价延迟15分钟
1.17B总市值
亏损市盈率 TTM

Castle Biosciences Inc

40.090
-0.110-0.27%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.27%

5天

+1.08%

1月

+4.16%

6月

+109.24%

今年开始到现在

+50.43%

1年

+44.62%

查看详细走势图

TradingKey Castle Biosciences Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

Castle Biosciences Inc当前公司基本面数据相对非常健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名9/206位。机构持股占比非常高,近一月多位分析师给出公司评级为强力买入。最高目标价37.75。中期看,股价处于上升通道。近一个月,市场表现一般,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Castle Biosciences Inc评分

相关信息

行业排名
9 / 206
全市场排名
57 / 4562
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 8 位分析师
强力买入
评级
37.750
目标均价
-0.92%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Castle Biosciences Inc亮点

亮点风险
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
业绩高增长
公司营业收入稳步增长,连续3年增长142.32%
业绩转盈
公司业绩转盈,最新年度盈利美元
估值低估
公司最新PE估值-97.28,处于3年历史低位
机构加仓
最新机构持股26.96M股,环比增加0.03%
先锋集团持仓
明星投资者先锋集团持仓,最新持仓市值2.16M
活跃度增加
近期活跃度增加,过去20天平均换手率0.95

Castle Biosciences Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Castle Biosciences Inc简介

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
公司代码CSTL
公司Castle Biosciences Inc
CEOMaetzold (Derek J)
网址https://castlebiosciences.com/

常见问题

Castle Biosciences Inc(CSTL)的当前股价是多少?

Castle Biosciences Inc(CSTL)的当前股价是 40.090。

Castle Biosciences Inc的股票代码是什么?

Castle Biosciences Inc的股票代码是CSTL。

Castle Biosciences Inc股票的52周最高点是多少?

Castle Biosciences Inc股票的52周最高点是40.610。

Castle Biosciences Inc股票的52周最低点是多少?

Castle Biosciences Inc股票的52周最低点是14.590。

Castle Biosciences Inc的市值是多少?

Castle Biosciences Inc的市值是1.17B。

Castle Biosciences Inc的净利润是多少?

Castle Biosciences Inc的净利润为18.25M。

现在Castle Biosciences Inc(CSTL)的股票是买入、持有还是卖出?

根据分析师评级,Castle Biosciences Inc(CSTL)的总体评级为--,目标价格为37.750。

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是多少

Castle Biosciences Inc(CSTL)股票的每股收益(EPS TTM)是-0.412。
KeyAI